Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia

Author(s): Alessandro Gozzetti*, Veronica Candi, Corrado Zuanelli Brambilla, Giulia Papini, Alberto Fabbri, Monica Bocchia.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 17 , Issue 8 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton’s tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.

Keywords: CLL, chemotherapy, BTK, BCR, tyrosine, kinase.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 8
Year: 2017
Page: [1040 - 1045]
Pages: 6
DOI: 10.2174/1871520616666160928153342
Price: $58

Article Metrics

PDF: 43
HTML: 2